SSTR2 and neoplasm: In contrast, preclinical studies conducted by Ahenkorah et al. comparaing the PET imaging characteristics between the antagonist [18F]AlF-NOTA-JR11 and the agonist [18F]AlF-NOTA-TATE in BONI.SSTR2 tumor bearing mice revealed comparable pharmacokinetics and similar tumor uptake of [18F]AlF-NOTA-JR11 (SUVmax: 3.7 ± 0.8) and [18F]AlF-NOTA-TATE (SUVmax: 3.6 ± 0.4) [8].